Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or Smaller.
Hepatocellular carcinoma
Intrahepatic distant recurrence
Radiofrequency ablation
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
17
12
2021
accepted:
14
02
2022
pubmed:
31
3
2022
medline:
16
11
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
Intrahepatic hepatocellular carcinoma (HCC) has a high recurrence rate after radiofrequency ablation (RFA). However, to date, no standalone predictive factors for intrahepatic distant recurrence after curative ablation have been reported. The aim of this study was to investigate predictive factors for intrahepatic distant recurrence after curative treatment with RFA for HCCs. This multicenter study consisted of 17 institutions that registered 821 patients. The risk factors for intrahepatic distant recurrence after complete ablation by RFA for primary HCC ≤ 2 cm in diameter were identified in a retrospectively collected training set (n = 636) and then validated in a prospectively collected validation set (n = 185). The cumulative intrahepatic distant and local recurrence rates (i.e., entire recurrence rate) in the training set were 23.6% and 53.7% at 1 and 3 years, respectively. The cumulative intrahepatic distant recurrence rates in the training set were 17.0% and 43.8% at 1 and 3 years, respectively. Multivariate analysis of the training set showed that tumor number and serum levels of α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) were independent risk factors for both entire recurrence and intrahepatic distant recurrence. Intrahepatic distant recurrence risk in both the training and validation cohorts was stratified using a scoring system with three factors: tumor number (single or multiple), AFP (< 10 ng/ml or ≥ 10 ng/ml), and DCP (< 50 mAU/ml or ≥ 50 mAU/ml). The scoring system composed of tumor number, AFP, and DCP is useful for classifying the risk of intrahepatic distant recurrence after curative ablation for HCC.
Sections du résumé
BACKGROUND
Intrahepatic hepatocellular carcinoma (HCC) has a high recurrence rate after radiofrequency ablation (RFA). However, to date, no standalone predictive factors for intrahepatic distant recurrence after curative ablation have been reported.
AIMS
The aim of this study was to investigate predictive factors for intrahepatic distant recurrence after curative treatment with RFA for HCCs.
METHODS
This multicenter study consisted of 17 institutions that registered 821 patients. The risk factors for intrahepatic distant recurrence after complete ablation by RFA for primary HCC ≤ 2 cm in diameter were identified in a retrospectively collected training set (n = 636) and then validated in a prospectively collected validation set (n = 185).
RESULTS
The cumulative intrahepatic distant and local recurrence rates (i.e., entire recurrence rate) in the training set were 23.6% and 53.7% at 1 and 3 years, respectively. The cumulative intrahepatic distant recurrence rates in the training set were 17.0% and 43.8% at 1 and 3 years, respectively. Multivariate analysis of the training set showed that tumor number and serum levels of α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) were independent risk factors for both entire recurrence and intrahepatic distant recurrence. Intrahepatic distant recurrence risk in both the training and validation cohorts was stratified using a scoring system with three factors: tumor number (single or multiple), AFP (< 10 ng/ml or ≥ 10 ng/ml), and DCP (< 50 mAU/ml or ≥ 50 mAU/ml).
CONCLUSION
The scoring system composed of tumor number, AFP, and DCP is useful for classifying the risk of intrahepatic distant recurrence after curative ablation for HCC.
Identifiants
pubmed: 35353331
doi: 10.1007/s10620-022-07455-2
pii: 10.1007/s10620-022-07455-2
doi:
Substances chimiques
alpha-Fetoproteins
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5704-5711Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
doi: 10.3322/caac.21492
pubmed: 30207593
Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
doi: 10.1002/hep.24199
pubmed: 21374666
Bruix J, Sherman M, Llovet JM, Beaugrand M et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the study of the liver. J Hepatol. 2001;35:421–430.
doi: 10.1016/S0168-8278(01)00130-1
pubmed: 11592607
Kokudo N, Takemura N, Hasegawa K, Takayama T et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109–1113.
doi: 10.1111/hepr.13411
pubmed: 31336394
Huang J, Yan L, Cheng Z, Wu H et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903–912.
doi: 10.1097/SLA.0b013e3181efc656
pubmed: 21107100
Kao WY, Chiou YY, Hung HH, Chou YH et al. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index. Eur J Gastroenterol Hepatol. 2011;23:528–536.
pubmed: 21537128
Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018;68:783–797.
doi: 10.1016/j.jhep.2017.10.004
pubmed: 29031662
Lee DH, Lee JM, Lee JY, Kim SH et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014;270:900–909.
doi: 10.1148/radiol.13130940
pubmed: 24475823
Kim YS, Lim HK, Rhim H, Lee MW et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89–97.
doi: 10.1016/j.jhep.2012.09.020
pubmed: 23023009
Shiina S, Tateishi R, Arano T, Uchino K et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107:569–577 (quiz 578).
doi: 10.1038/ajg.2011.425
pubmed: 22158026
Hasegawa K, Kokudo N, Makuuchi M, Izumi N et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol. 2013;58:724–729.
doi: 10.1016/j.jhep.2012.11.009
pubmed: 23178708
Fuke H, Sugimoto K, Shiraki K, Tanaka J et al. Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization. Aliment Pharmacol Ther. 2008;27:1253–1260.
doi: 10.1111/j.1365-2036.2008.03627.x
pubmed: 18221404
Imai K, Beppu T, Chikamoto A, Doi K et al. Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res. 2013;43:853–864.
doi: 10.1111/hepr.12035
pubmed: 23281579
Yoo J, Lee MW, Lee DH, Lee JH, Han JK. Evaluation of a serum tumor marker-based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma. Liver Int. 2020;40:1189–1200.
doi: 10.1111/liv.14406
pubmed: 32056353
Chu MO, Shen CH, Chang TS, Xu HW et al. Pretreatment inflammation-based markers predict survival outcomes in patients with early-stage hepatocellular carcinoma after radiofrequency ablation. Sci Rep. 2018;8:16611.
doi: 10.1038/s41598-018-34543-z
pubmed: 30413724
pmcid: 6226503
Yu SJ, Kwon JH, Kim W, Yoon JH et al. Initial alpha-fetoprotein response predicts prognosis in hepatitis B-related solitary HCC patients after radiofrequency ablation. J Clin Gastroenterol. 2018;52:e18–e26.
doi: 10.1097/MCG.0000000000000841
pubmed: 28795996
Dohi C, Nouso K, Miyahara K, Morimoto Y et al. Potential of alpha-fetoprotein as a prognostic marker after curative radiofrequency ablation of hepatocellular carcinoma. Hepatol Res. 2016;46:916–923.
doi: 10.1111/hepr.12636
pubmed: 26670077
Ueno M, Hayami S, Shigekawa Y, Kawai M et al. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ≤ 5 cm: cohort study based on serum HCC markers. J Hepatol. 2015;63:1352–1359.
doi: 10.1016/j.jhep.2015.07.013
pubmed: 26212030
Chen K, Zhan MX, Hu BS, Li Y et al. Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma. Oncol Lett. 2018;15:315–323.
pubmed: 29285194
N’Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009;50:1475–1483.
doi: 10.1002/hep.23181
pubmed: 19731239
Harimoto N, Yoshizumi T, Sakata K, Nagatsu A et al. Prognostic significance of preoperative controlling nutritional status (CONUT) score in patients undergoing hepatic resection for hepatocellular carcinoma. World J Surg. 2017;41:2805–2812.
doi: 10.1007/s00268-017-4097-1
pubmed: 28653142
Takagi K, Yagi T, Umeda Y, Shinoura S et al. Preoperative controlling nutritional status (CONUT) score for assessment of prognosis following hepatectomy for hepatocellular carcinoma. World J Surg. 2017;41:2353–2360.
doi: 10.1007/s00268-017-3985-8
pubmed: 28389736
Hansmann J, Evers MJ, Bui JT, Lokken RP et al. Albumin-bilirubin and platelet-albumin-bilirubin grades accurately predict overall survival in high-risk patients undergoing conventional transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2017;28:1224–31.e2.
doi: 10.1016/j.jvir.2017.05.020
pubmed: 28688815
Hiraoka A, Kumada T, Hirooka M, Tsuji K et al. A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: usefulness of albumin-bilirubin grade. Hepatol Res. 2018;48:E61–E67.
doi: 10.1111/hepr.12927
pubmed: 28628718
Toyoda H, Kumada T, Kiriyama S, Sone Y et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:111–117.
doi: 10.1016/S1542-3565(05)00855-4
pubmed: 16431313
Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: an updated review. World J Gastrointest Pharmacol Ther. 2016;7:477–489.
doi: 10.4292/wjgpt.v7.i4.477
pubmed: 27867681
pmcid: 5095567